We are progressing in the diagnosis of Alzheimer’s disease

We work with scientific research projects to prevent Alzheimer’s disease and other age-related illnesses, delay their onset and improve people’s health and quality of life.

ALFA Study (Alzheimer and Families). Pasqual Maragall Foundation

Since 2008, this pioneering project has been focused on preparing a study aimed at early diagnosis of Alzheimer’s disease. The ALFA (Alzheimer and Families) cognitive and genetic assessment study used over 2,700 healthy participants aged between 45 and 65 to gather information to help prevent or delay the onset of Alzheimer’s disease.


Project Gr@ACE, genomic research into Alzheimer’s disease.

The ACE foundation will be carrying out the GR@ACE project over a three-year period (from 2016 to 2019) with the backing of the ”la Caixa” Foundation and the Grífols Foundation.

This the Alzheimer’s research project with the most genome samples (nearly 4,000) carried out so far in Spain. The study is based on the use of high-resolution genome technology to identify a new generation of genes to determine new therapeutic targets for treating this illness.


Identifying epigenetic biomarkers in Alzheimer’s disease and other neurodegenerative disorders. Miguel Servet Foundation and the Navarrabiomed Biomedical Research Centre

The purpose of this project is to identify epigenetic biomarkers in peripheral blood from patients with Alzheimer’s disease to contribute to improving the diagnosis, prognosis and treatment of the illness.

This project is aimed at patients in the initial stages of the illness and the population at risk of developing it. It is a transversal study of cases and controls, recruiting a group of seventy-five patients with the possibility of developing Alzheimer’s disease, and seventy-five control patients paired by age and gender. The aim of this is to create a non-invasive, accessible diagnostic test using a blood analysis, to help improve diagnosis and early detection of the disease.


DABNI (Down Alzheimer Barcelona Neuroimaging Initiative) Study. Santa Creu i Sant Pau Hospital Research Institute

The aim of this study is to identify biomarkers of cognitive deterioration and the early detection of Alzheimer’s disease in people with Down’s syndrome.

The increased life expectancy of people with Down’s syndrome, which is currently on average over sixty years, has led to the appearance of neurodegenerative diseases. Thus, 80% of people with Down’s syndrome aged over sixty display symptoms of Alzheimer’s disease.

1,000 volunteers with Down’s syndrome took part in this study, undergoing specific tests to assess the possibility of their developing Alzheimer’s disease.